A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Pulmonary hypertension; Right ventricular dysfunction
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
    • 22 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2018.
    • 29 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top